Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says

The Trump Administration remains convinced that rebates lead to high list prices and that reform of the system is needed, US HHS Deputy Secretary Eric Hargan emphasizes.

Rebates_535538281_1200.jpg

Pfizer Inc.’s recent disclosure that it would be raising list prices on some of its prescription drugs next year is a case in point on why the current system of rebates must change, HHS Deputy Secretary Eric Hargan pointed out during the FDA/CMS Summit in Washington D.C. Dec. 12.

Pfizer announced in November that it would increase prices on 41 drugs, representing 10% of its portfolio, in mid-January. Increases...

More from Pricing Debate

More from Market Access